Stryker announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. The acquisition will strengthen Stryker’s offerings in the soft tissue fixation segment and highlights Stryker’s commitment to providing differentiated solutions for ligament and tendon reconstruction. Artelon’s technologies complement and expand the current range of products available to Stryker’s foot and ankle and sports medicine specialist customers. Its differentiated synthetic technology is designed to enhance biological and mechanical ligament and tendon reconstruction, with over 60,000 implantations worldwide. The acquisition will also allow Stryker to position itself more competitively in the foot and ankle and sports medicine segment with an innovative biomaterial technology that supports the healing of the patient’s soft tissues… This transaction is subject to customary closing conditions. Stryker and Artelon will continue to operate as separate entities and proceed with business as usual until the transaction closes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- ZTS, SYK, LLY: Which Healthcare Stock Is the Best Buy?
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Stryker initiated with a Neutral at Goldman Sachs
- Stryker announces first Gamma4 Hip Fracture Nailing System surgeries in Europe
- Anika enters cooperation pact with Caligan, appoints two new directors to board